Reckitt Benckiser Newswire (Page 7)

Comprehensive Real-Time News Feed for Reckitt Benckiser. (Page 7)

Results 121 - 140 of 1,198 in Reckitt Benckiser

  1. What Should Merck Do With Its $14 Billion Windfall?Read the original story

    May 7, 2014 | The Motley Fool

    Bayer's $14 billion offer outbid competitors Reckitt Benckiser , Procter & Gamble , Novartis , and Sanofi for the segment, which includes popular brands including Claritin and Coppertone.

    Comment?

  2. Dorel Industries missed the rally. Will it pick up?Read the original story w/Photo

    May 6, 2014 | Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. Investors whacked biotech and tech stocks leading the Nasdaq to its deepest percentage slump since ...

    Comment?

  3. Merck makes wise wager on promising cancer drugRead the original story w/Photo

    May 6, 2014 | The Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. The company's consumer care business is small. Sales last year were $1.9-billion, or less than 5 per ...

    Comment?

  4. Ackman urges Allergan to negotiate with ValeantRead the original story w/Photo

    May 5, 2014 | The Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. Bausch & Lomb eye care products on display at Maximart Pharmacy in Palo Alto, Calif., on May 16, ...

    Comment?

  5. Pfizer revenue misses forecasts as generic sales slideRead the original story w/Photo

    May 5, 2014 | The Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. Total first-quarter revenue fell 9 per cent to $11.35-billion, which was $730-million below Wall ...

    Comment?

  6. Valeant results will seek to make case for AllerganRead the original story

    May 4, 2014 | The Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. Valeant, based in Montreal, will get the chance to underline its strong financial footing on ...

    Comment?

  7. Bond, stock investors making hay; can both be right?Read the original story w/Photo

    May 4, 2014 | The Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. "The data are suggesting this may be the year when we turn the corner," said Quincy Krosby, market ...

    Comment?

  8. LinkedIn swings to first-quarter loss on higher spendingRead the original story

    May 1, 2014 | The Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. Lloyds Banking Group's pretax profit jumped 22 percent in the first quarter as costs fell and margins ...

    Comment?

  9. Zenith MENA Wins Reckitt Benckiser Arabia's Digital BusinessRead the original story w/Photo

    May 4, 2014 | AME Info

    ... staff. a Presentations to senior staff a Requirements to communicate across the business FMCG giant Reckitt Benckiser has selected Zenith MENA - the Middle East's top 'ROI Agency' - to manage its digital media operations following a competitive, ...

    Comment?

  10. A fund manager who refunds fees? Meet Francis ChouRead the original story w/Photo

    May 2, 2014 | Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. Mobile telecom gear maker Ericsson posted sales and fourth-quarter operating profit below ...

    Comment?

  11. Pfizer enters takeover discussions with AstraZeneca: reportRead the original story w/Photo

    May 1, 2014 | The Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. Merck offset patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its ...

    Comment?

  12. Pharma M&A: It's BackRead the original story

    May 1, 2014 | The Motley Fool

    ... be left out, Eli Lilly ( ) is reportedly looking for a buyer for its consumer health-care unit. Bayer and Reckitt Benckiser appear to be the top contenders for the unit that could go for roughly $13.5 billion. In the video below, senior biotech ...

    Comment?

  13. Pfizer may sweeten bid for AstraZenecaRead the original story w/Photo

    May 1, 2014 | The Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. Merck offset patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its ...

    Comment?

  14. At midday: TSX edges higher amid earnings, economic dataRead the original story w/Photo

    May 1, 2014 | Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. The number of Americans applying for unemployment benefits rose 14,000 to 344,000 last week, the ...

    Comment?

  15. Press Digest- British Business - May 1Read the original story

    Apr 30, 2014 | AlertNet

    ... pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. Reckitt Benckiser has said it is no longer in discussions about buying U.S. pharma group Merck's consumer health business, leaving Germany's ...

    Comment?

  16. Split won't help Energizer Bunny fend off the P&G gorillaRead the original story w/Photo

    Apr 30, 2014 | The Globe and Mail

    ... patent expirations on drugs by drastically slashing R&D costs. It's in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports. Nokia announces plans to return more than $3 billion to shareholders. Hayley Platt asks if the new ...

    Comment?

  17. Reckitt Benckiser ends Merck acquisition talksRead the original story

    Apr 30, 2014 | Live Charts

    Consumer products giant Reckitt Benckiser announced after hours on Wednesday that it was no longer in talks with Merck to buy the US pharmaceutical company's consumer health business.

    Comment?

  18. UPDATE 2-Reckitt Benckiser says no longer in talks with MerckRead the original story

    Apr 30, 2014 | Reuters

    Reckitt Benckiser Group said on Wednesday it was no longer in active talks with Merck & Co about buying its consumer health business, leaving Germany's Bayer as the leading contender for the $14 billion business.

    Comment?

  19. Now Available: Surface Care in the United Arab EmiratesRead the original story

    Apr 30, 2014 | SBWire

    In 2013 there was increased awareness of antibacterial products and health, mainly led by marketing campaigns carried out by multinational brands such as Dettol by Reckitt Benckiser through television commercials.

    Comment?

  20. New Market Report: Reckitt BenckiserRead the original story

    Apr 29, 2014 | PR-inside.com

    Reckitt Benckiser is expected to invest in home care, consumer healthcare, and personal care in order to drive sales growth in the country.

    Comment?